L A Solé - JoVE Visualize

Showing results (11-20 of 18) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 18 results.

Acta Oncologica (Stockholm, Sweden)|January 1, 1997

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF scheduleA Ribas, J Albanell, J Bellmunt, et al.

Cancer|March 5, 1998

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinomaA Ribas, J Albanell, L A Solé-Calvo, et al.

Acta Oncologica (Stockholm, Sweden)|January 1, 1995

Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in SpainA Ribas, J Bellmunt, J Albanell, et al.

Cancer|October 1, 1992

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapyJ Bellmunt, J Albanell, O S Gallego, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.

Revista Espanola De Oncologia|January 1, 1984

[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]A Ruibal, P Durán, A Lafuerza, et al.

Anticancer Research|March 1, 1996

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.

Archivos Espanoles De Urologia|June 1, 1996

[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]J Bellmunt Molins, A Ribas, J Albanell, et al.

Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 18 results.

Acta Oncologica (Stockholm, Sweden)|January 1, 1997

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF scheduleA Ribas, J Albanell, J Bellmunt, et al.

Cancer|March 5, 1998

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinomaA Ribas, J Albanell, L A Solé-Calvo, et al.

Acta Oncologica (Stockholm, Sweden)|January 1, 1995

Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in SpainA Ribas, J Bellmunt, J Albanell, et al.

Cancer|October 1, 1992

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapyJ Bellmunt, J Albanell, O S Gallego, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.

Revista Espanola De Oncologia|January 1, 1984

[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]A Ruibal, P Durán, A Lafuerza, et al.

Anticancer Research|March 1, 1996

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.

Archivos Espanoles De Urologia|June 1, 1996

[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]J Bellmunt Molins, A Ribas, J Albanell, et al.

Pageof 2